Long Noncoding RNA E2F1 Messenger RNA Stabilizing Factor (EMS) Promotes Sorafenib Resistance in Renal Cell Carcinoma by Regulating miR-363-3p and Dual-Specificity Phosphatase 10 Expression.

Renal cell carcinoma (RCC) is a common kidney disease associated with high mortality. Sorafenib is a protein kinase inhibitor that targets multiple kinases and is used for treating different cancers, including RCC. However, sorafenib resistance in patients with RCC hampers its use.